Harvard Apparatus Regenerative Tech Inc (NASDAQ:HART) CEO Jim McGorry is set to hold a special investor event next week on December 1 in Lost Angeles, California. This apparently has given investors reason for hope, as the stock jump quite a bit today, on relatively high trading volume.
It should be interesting to follow the investor event to see what this company has to announce (if anything). Harvard Apparatus is developing bioengineered organs for life-threatening conditions.
According to the official press release on Wednesday:
“Jim McGorry will review the company’s business strategy and opportunities and comment on HART’s recent animal studies that revealed significant results from its second generation (Gen2) bioengineered implant platform for the esophagus, trachea and bronchus, as well as the company’s near-term milestones. HART has initiated confirmatory large-animal studies of its Gen2 implants in collaboration with Mayo Clinic.”
The stock increased 25.36% or $0.45 during the last trading session, hitting $2.2. About 2.97 million shares traded hands or 77.84% up from the average. HART has declined 43.57% since April 24, 2015 and is downtrending. It has underperformed by 42.21% the S&P500.
The institutional sentiment increased to 0.76 in Q2 2015. Its up 0.11, from 0.65 in 2015Q1. The ratio is positive, as 8 funds sold all Harvard Apparatus Regenerative Tech Inc shares owned while 9 reduced positions. 3 funds bought stakes while 10 increased positions. They now own 2.64 million shares or 18.87% less from 3.26 million shares in 2015Q1.
Penbrook Management Llc holds 0.17% of its portfolio in Harvard Apparatus Regenerative Tech Inc for 126,583 shares. Sio Capital Management Llc owns 232,712 shares or 0.16% of their US portfolio. Moreover, Granahan Investment Management Inc Ma has 0.01% invested in the company for 195,915 shares. The New Jersey-based Nj State Employees Deferred Compensation Plan has invested 0.01% in the stock. A.R.T. Advisors Llc, a New York-based fund reported 21,833 shares.
Since September 21, 2015, the stock had 1 insider buy, and 0 sales for $12,210 net activity. Lafrancesca Saverio bought 9,500 shares worth $12,210.
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology firm making regenerated organs for transplant. The company has a market cap of $29.60 million. The Company’s product, the HART-Trachea, is intended to be used to restore the structure and/or function of a severely damaged trachea . It currently has negative earnings. The HART-Trachea comprises the patient’s own bone marrow cells seeded on the Company’s InBreath porous plastic scaffold in its InBreath organ bioreactor.